Indication

BRCA1/2 Mutations

1 clinical trial

1 product

Clinical trial

A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients With Germline or Somatic BRCA1/2 Mutations.

Status: Completed, Estimated PCD: 2021-10-08

Product